Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The pharmacogenomic profiles of drug metabolizing enzymes play an important role in
pharmacokinetics (PK) of drugs. Phenobarbital (PB), worldwidely used for neonatal seizure, is
a drug that requires careful dose adjustments based on therapeutic drug monitoring. It was
reported that phenobarbital (PB) metabolism was affected by CYP2C9 and CYP2C19 polymorphisms
in adults. This study aims to evaluate the effects of the CYP2C9 and CYP2C19 genetic
polymorphisms on PB PK in infants with neonatal seizure for an optimal dosing strategy.